Repare shareholders approve acquisition by XenoTherapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
January 16, 2026 4:58 PM ESTCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the Common Shares and the holders of the Common Shares, the Shareholders) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly Xeno) a non-profit biotechnology company, by way of a statutory plan of arrangement (the Transaction or the Arrangement) at the special meeting of Shareholders held today (the Meeting).
The special resolution approving the Arrangement was approved... More
